Announcement • Jul 28
Bharat Parenterals Limited to Report Q1, 2027 Results on Aug 05, 2026 Bharat Parenterals Limited announced that they will report Q1, 2027 results on Aug 05, 2026 New Risk • May 20
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 41% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 47% per year over the past 5 years. Minor Risks High level of debt (41% net debt to equity). Market cap is less than US$100m (₹8.60b market cap, or US$89.0m). Reported Earnings • May 20
Full year 2026 earnings released: ₹39.62 loss per share (vs ₹19.27 loss in FY 2025) Full year 2026 results: ₹39.62 loss per share. Revenue: ₹3.55b (up 4.3% from FY 2025). Net loss: ₹81.9m (loss narrowed 35% from FY 2025). Announcement • May 09
Bharat Parenterals Limited to Report Q4, 2026 Results on May 18, 2026 Bharat Parenterals Limited announced that they will report Q4, 2026 results on May 18, 2026 New Risk • Apr 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 43% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (₹7.20b market cap, or US$77.2m). Reported Earnings • Jan 31
Third quarter 2026 earnings released Third quarter 2026 results: ₹14.03 loss per share. Revenue: ₹651.9m (down 9.8% from 3Q 2025). Net loss: ₹43.9m (loss widened 161% from 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 111 percentage points per year, which is a significant difference in performance. Announcement • Jan 22
Bharat Parenterals Limited to Report Q3, 2026 Results on Jan 30, 2026 Bharat Parenterals Limited announced that they will report Q3, 2026 results on Jan 30, 2026 Reported Earnings • Nov 13
Second quarter 2026 earnings released Second quarter 2026 results: Revenue: ₹681.5m (down 4.9% from 2Q 2025). Net loss: ₹72.4m (loss narrowed 3.6% from 2Q 2025). Announcement • Nov 08
Bharat Parenterals Limited to Report Q2, 2026 Results on Nov 12, 2025 Bharat Parenterals Limited announced that they will report Q2, 2026 results on Nov 12, 2025 Announcement • Sep 27
Bharat Parenterals Limited Approves Regularization of Additional Director Alkesh Jayantilal Shah, as Non-Executive Director Bharat Parenterals Limited at its AGM held on September 26, 2025, approved the regularization of Additional Director Mr. Alkesh Jayantilal Shah, appointed as Non-Executive Director. New Risk • Sep 26
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₹8.51b (US$95.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 35% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹8.51b market cap, or US$95.9m). Upcoming Dividend • Sep 12
Upcoming dividend of ₹1.00 per share Eligible shareholders must have bought the stock before 19 September 2025. Payment date: 26 October 2025. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%). Announcement • Jul 29
Bharat Parenterals Limited, Annual General Meeting, Sep 26, 2025 Bharat Parenterals Limited, Annual General Meeting, Sep 26, 2025. Reported Earnings • Jul 29
First quarter 2026 earnings released First quarter 2026 results: Revenue: ₹1.17b (up 27% from 1Q 2025). Net income: ₹82.3m (up ₹69.5m from 1Q 2025). Profit margin: 7.0% (up from 1.4% in 1Q 2025). The increase in margin was driven by higher revenue. Announcement • Jul 22
Bharat Parenterals Limited to Report Q1, 2026 Results on Jul 28, 2025 Bharat Parenterals Limited announced that they will report Q1, 2026 results on Jul 28, 2025 New Risk • May 15
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 29% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (₹7.23b market cap, or US$84.4m). Reported Earnings • May 13
Full year 2025 earnings released: ₹66.64 loss per share (vs ₹24.94 profit in FY 2024) Full year 2025 results: ₹66.64 loss per share (down from ₹24.94 profit in FY 2024). Revenue: ₹3.52b (up 36% from FY 2024). Net loss: ₹126.3m (down 187% from profit in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 112 percentage points per year, which is a significant difference in performance. Announcement • May 13
Bharat Parenterals Limited Recommends Final Dividend for the Financial Year Ended March 31, 2025 Board of directors of Bharat Parenterals Limited at the meeting held on May 12, 2025, have inter-alia: Recommendation of final dividend of INR 1.00/- per equity share of INR 10/- each (at the rate of 10%) for financial year ended March 31, 2025. The dividend, if approved by the members at upcoming Annual General Meeting, will be dispatched /remitted within 30 days from the date of declaration. Announcement • May 05
Bharat Parenterals Limited to Report Q4, 2025 Results on May 12, 2025 Bharat Parenterals Limited announced that they will report Q4, 2025 results on May 12, 2025 Announcement • Apr 25
Bharat Parenterals Limited (BSE:541096) agreed to acquire Varenyam Healthcare Private Limited from Bharat Desai, Himaben Bharatkumar Desai, Bhahim Bharatkumar Desai and Nikita Bhahim Desai for approximately INR 470 million . Bharat Parenterals Limited (BSE:541096) agreed to acquire Varenyam Healthcare Private Limited from Bharat Desai, Himaben Bharatkumar Desai, Bhahim Bharatkumar Desai and Nikita Bhahim Desai for approximately INR 460 million on June 5, 2024. As of October 29, 2024, Nikita Bhahim Desai received 0.08 million equity shares of Bharat Parenterals Limited. The consideration consists of 0.35 million common equity of Bharat Parenterals Limited to be issued for 0.25 million common equity of Varenyam Healthcare Private Limited. The consideration is subject to closing adjustments. For the period ending March 31, 2024, Varenyam Healthcare Private Limited reported total revenue of INR 103.22. The transaction is subject to approval of the shareholders of Bharat Parenterals Ltd and other approvals. The deal has been approved by the Board of Directors of Bharat Parenterals Ltd. The deal is expected to be completed by June 30, 2024.
Bharat Parenterals Limited (BSE:541096) completed the acquisition of Varenyam Healthcare Private Limited from Bharat Desai, Himaben Bharatkumar Desai, Bhahim Bharatkumar Desai and Nikita Bhahim Desai for approximately INR 470 million on April 24, 2025. Reported Earnings • Feb 04
Third quarter 2025 earnings released Third quarter 2025 results: Revenue: ₹722.6m (up 21% from 3Q 2024). Net loss: ₹16.8m (down 144% from profit in 3Q 2024). New Risk • Jan 27
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₹8.35b (US$96.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 14% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹8.35b market cap, or US$96.8m). Announcement • Jan 23
Bharat Parenterals Limited to Report Q3, 2025 Results on Feb 03, 2025 Bharat Parenterals Limited announced that they will report Q3, 2025 results on Feb 03, 2025 Announcement • Jan 17
Bharat Parenterals Limited Announces Resignation of Krutika Bhattbhatt, Company Secretary and Compliance Officer Bharat Parenterals Limited informed that Ms. Krutika Bhattbhatt, Company Secretary and Compliance Officer (Key Managerial Personnel) of the Company and its material subsidiary has resigned from the position of Company Secretary & Compliance Officer (Key Managerial Personnel) of the Company vide her resignation letter dated 28th November 2024. Reported Earnings • Oct 30
Second quarter 2025 earnings released: ₹27.00 loss per share (vs ₹6.07 profit in 2Q 2024) Second quarter 2025 results: ₹27.00 loss per share (down from ₹6.07 profit in 2Q 2024). Revenue: ₹758.4m (up 27% from 2Q 2024). Net loss: ₹75.1m (down 313% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 55% per year, which means it is well ahead of earnings. Announcement • Oct 20
Bharat Parenterals Limited to Report Q2, 2025 Results on Oct 29, 2024 Bharat Parenterals Limited announced that they will report Q2, 2025 results on Oct 29, 2024 Reported Earnings • Aug 09
First quarter 2025 earnings released: ₹14.71 loss per share (vs ₹13.03 profit in 1Q 2024) First quarter 2025 results: ₹14.71 loss per share (down from ₹13.03 profit in 1Q 2024). Revenue: ₹950.5m (up 36% from 1Q 2024). Net income: ₹12.8m (down 83% from 1Q 2024). Profit margin: 1.3% (down from 11% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 63% per year, which means it is well ahead of earnings. Announcement • Aug 01
Bharat Parenterals Limited to Report Q1, 2025 Results on Aug 08, 2024 Bharat Parenterals Limited announced that they will report Q1, 2025 results on Aug 08, 2024 Announcement • Jun 25
Bharat Parenterals Limited (BSE:541096) agreed to acquire an unknown majority stake in Varenyam Biolifesciences Private Limited for INR 22.56 million. Bharat Parenterals Limited (BSE:541096) agreed to acquire an unknown majority stake in Varenyam Biolifesciences Private Limited for INR 22.56 million on June 24, 2024. Upcoming Dividend • Jun 18
Upcoming dividend of ₹1.00 per share Eligible shareholders must have bought the stock before 25 June 2024. Payment date: 01 August 2024. Payout ratio is a comfortable 4.0% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.1%). Lower than average of industry peers (0.8%). Announcement • Jun 14
Bharat Parenterals Limited, Annual General Meeting, Jul 02, 2024 Bharat Parenterals Limited, Annual General Meeting, Jul 02, 2024, at 11:00 Indian Standard Time. New Risk • Jun 08
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 13% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 2.8% per year over the past 5 years. High level of non-cash earnings (39% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (5.6% net profit margin). Shareholders have been diluted in the past year (13% increase in shares outstanding). New Risk • May 28
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₹8.13b (US$97.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 2.8% per year over the past 5 years. High level of non-cash earnings (38% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Profit margins are more than 30% lower than last year (5.5% net profit margin). Market cap is less than US$100m (₹8.13b market cap, or US$97.7m). Reported Earnings • May 23
Full year 2024 earnings released: EPS: ₹24.94 (vs ₹42.14 in FY 2023) Full year 2024 results: EPS: ₹24.94 (down from ₹42.14 in FY 2023). Revenue: ₹2.66b (up 21% from FY 2023). Net income: ₹145.2m (down 40% from FY 2023). Profit margin: 5.5% (down from 11% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 12
Bharat Parenterals Limited to Report Q4, 2024 Results on May 22, 2024 Bharat Parenterals Limited announced that they will report Q4, 2024 results on May 22, 2024 Announcement • May 01
Bharat Parenterals Limited announced that it expects to receive INR 981.500535 million in funding Bharat Parenterals Limited announced a private placement of 723,607 equity shares for the gross proceeds of INR 1356.40 for the gross proceeds of INR 981,500,535 on April 29, 2024. The shares will be issued on preferential basis. The transaction will include participation from new investors, NEO APEX SHARE BROKING SERVICES LLP for 88,469.48 shares, AJEET JALAN for 29,489.83 shares, AMRUTLAL NARANDAS GANATRA HUF for 7,372.457 shares, Rajiv Agarwal for 7,372.457 shares, Ashish Kacholia for 129,018 shares and other investors. The transaction has been approved by the shareholders of the company. Valuation Update With 7 Day Price Move • Apr 23
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹1,540, the stock trades at a trailing P/E ratio of 35.6x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 289% over the past three years. New Risk • Apr 20
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risk Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • Apr 08
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹1,330, the stock trades at a trailing P/E ratio of 30.7x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 281% over the past three years. Valuation Update With 7 Day Price Move • Mar 13
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹1,086, the stock trades at a trailing P/E ratio of 25.1x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 209% over the past three years. Valuation Update With 7 Day Price Move • Feb 20
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹1,073, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 211% over the past three years. Reported Earnings • Feb 14
Third quarter 2024 earnings released: EPS: ₹6.45 (vs ₹4.94 in 3Q 2023) Third quarter 2024 results: EPS: ₹6.45 (up from ₹4.94 in 3Q 2023). Revenue: ₹610.8m (up 3.5% from 3Q 2023). Net income: ₹37.8m (up 33% from 3Q 2023). Profit margin: 6.2% (up from 4.8% in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Feb 01
Bharat Parenterals Limited to Report Q3, 2023 Results on Feb 13, 2024 Bharat Parenterals Limited announced that they will report Q3, 2023 results on Feb 13, 2024 Valuation Update With 7 Day Price Move • Dec 19
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to ₹767, the stock trades at a trailing P/E ratio of 18.4x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 116% over the past three years. Reported Earnings • Nov 14
Second quarter 2024 earnings released: EPS: ₹6.07 (vs ₹17.19 in 2Q 2023) Second quarter 2024 results: EPS: ₹6.07 (down from ₹17.19 in 2Q 2023). Revenue: ₹624.1m (down 24% from 2Q 2023). Net income: ₹35.2m (down 65% from 2Q 2023). Profit margin: 5.6% (down from 12% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings. Board Change • Nov 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Non Executive Director Sanjay Shah was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Oct 01
Bharat Parenterals Limited Declares Dividend for the Financial Year 2022 to 2023 Bharat Parenterals Limited declared dividend of INR 0.75 (7.5%) per ordinary (equity) share of face value INR 10 each for the financial year 2022 to 2023. Announcement • Sep 02
Bharat Parenterals Limited, Annual General Meeting, Sep 30, 2023 Bharat Parenterals Limited, Annual General Meeting, Sep 30, 2023, at 10:30 Indian Standard Time. Valuation Update With 7 Day Price Move • Aug 16
Investor sentiment improves as stock rises 34% After last week's 34% share price gain to ₹632, the stock trades at a trailing P/E ratio of 16x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 52% over the past three years. New Risk • Aug 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (₹3.56b market cap, or US$42.9m). Reported Earnings • Aug 10
First quarter 2024 earnings released: EPS: ₹13.03 (vs ₹2.03 in 1Q 2023) First quarter 2024 results: EPS: ₹13.03 (up from ₹2.03 in 1Q 2023). Revenue: ₹720.1m (up 176% from 1Q 2023). Net income: ₹75.2m (up ₹63.5m from 1Q 2023). Profit margin: 10% (up from 4.5% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings. Announcement • Aug 03
Bharat Parenterals Limited to Report Q1, 2024 Results on Aug 09, 2023 Bharat Parenterals Limited announced that they will report Q1, 2024 results on Aug 09, 2023 Announcement • Jun 10
Bharat Parenterals Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023 Bharat Parenterals Limited has recommended payment of final dividend of INR 0.75 (Rupees Seventy-Five Paise Only) per Equity Share of INR 10 each (fully paid-up) for the financial year ended March 31, 2023 and the same shall be payable subject To Approve the Shareholders at the upcoming Annual General Meeting (AGM) of the Company. Reported Earnings • May 21
Full year 2023 earnings released: EPS: ₹28.40 (vs ₹36.68 in FY 2022) Full year 2023 results: EPS: ₹28.40 (down from ₹36.68 in FY 2022). Revenue: ₹2.30b (up 8.2% from FY 2022). Net income: ₹164.4m (down 22% from FY 2022). Profit margin: 7.2% (down from 9.9% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. Announcement • May 07
Bharat Parenterals Limited to Report Q4, 2023 Results on May 20, 2023 Bharat Parenterals Limited announced that they will report Q4, 2023 results on May 20, 2023 Reported Earnings • Feb 14
Third quarter 2023 earnings released: EPS: ₹4.94 (vs ₹2.32 in 3Q 2022) Third quarter 2023 results: EPS: ₹4.94 (up from ₹2.32 in 3Q 2022). Revenue: ₹625.0m (up 63% from 3Q 2022). Net income: ₹28.5m (up 114% from 3Q 2022). Profit margin: 4.6% (up from 3.5% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Dec 13
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₹325, the stock trades at a trailing P/E ratio of 11.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 91% over the past three years. Reported Earnings • Nov 16
Second quarter 2023 earnings released: EPS: ₹17.19 (vs ₹13.88 in 2Q 2022) Second quarter 2023 results: EPS: ₹17.19 (up from ₹13.88 in 2Q 2022). Revenue: ₹883.1m (up 46% from 2Q 2022). Net income: ₹99.2m (up 25% from 2Q 2022). Profit margin: 11% (down from 13% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 33% per year, which means it is well ahead of earnings. Announcement • Aug 30
Bharat Parenterals Limited, Annual General Meeting, Sep 27, 2022 Bharat Parenterals Limited, Annual General Meeting, Sep 27, 2022, at 10:30 Indian Standard Time. Reported Earnings • Aug 13
First quarter 2023 earnings released: EPS: ₹2.03 (vs ₹13.49 in 1Q 2022) First quarter 2023 results: EPS: ₹2.03 (down from ₹13.49 in 1Q 2022). Revenue: ₹260.9m (down 57% from 1Q 2022). Net income: ₹11.7m (down 85% from 1Q 2022). Profit margin: 4.5% (down from 13% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings. Reported Earnings • Jun 03
Full year 2022 earnings released: EPS: ₹36.67 (vs ₹35.59 in FY 2021) Full year 2022 results: EPS: ₹36.67 (up from ₹35.59 in FY 2021). Revenue: ₹2.20b (up 6.1% from FY 2021). Net income: ₹210.5m (up 3.2% from FY 2021). Profit margin: 9.6% (in line with FY 2021). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • May 20
Investor sentiment improved over the past week After last week's 15% share price gain to ₹359, the stock trades at a trailing P/E ratio of 11x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 78% over the past three years. Announcement • May 17
Bharat Parenterals Limited to Report Q4, 2022 Results on May 28, 2022 Bharat Parenterals Limited announced that they will report Q4, 2022 results on May 28, 2022 Valuation Update With 7 Day Price Move • Apr 05
Investor sentiment improved over the past week After last week's 18% share price gain to ₹375, the stock trades at a trailing P/E ratio of 11.5x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 77% over the past three years. Buying Opportunity • Feb 24
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 18%. The fair value is estimated to be ₹393, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.0% per annum over the last 3 years. Earnings per share has grown by 3.4% per annum over the last 3 years. Valuation Update With 7 Day Price Move • Feb 16
Investor sentiment deteriorated over the past week After last week's 19% share price decline to ₹340, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 44% over the past three years. Reported Earnings • Feb 10
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹2.32 (down from ₹9.46 in 3Q 2021). Revenue: ₹397.7m (down 20% from 3Q 2021). Net income: ₹13.8m (down 75% from 3Q 2021). Profit margin: 3.5% (down from 11% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Nov 03
Second quarter 2022 earnings released: EPS ₹13.88 (vs ₹11.26 in 2Q 2021) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: ₹629.2m (up 5.6% from 2Q 2021). Net income: ₹79.5m (up 23% from 2Q 2021). Profit margin: 13% (up from 11% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Jun 06
Full year 2021 earnings released: EPS ₹35.59 (vs ₹42.14 in FY 2020) The company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2021 results: Revenue: ₹2.13b (down 8.4% from FY 2020). Net income: ₹203.9m (down 16% from FY 2020). Profit margin: 9.6% (in line with FY 2020). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • May 28
Investor sentiment improved over the past week After last week's 21% share price gain to ₹470, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 133% over the past three years. Announcement • May 23
Bharat Parenterals Limited Receives the License and Authorization from Drugs Controller General of India and Central Drugs Standard Control Organization, New Delhi Bharat Parenterals Limited announced that it has received the license and authorization from drugs controller general of India and central drugs standard control organization, New Delhi for the manufacturing and marketing of "FAVIPIRAVIR ORAL SUSPENSION 100mg/ml" which will be used for treatment of COVID-19 disease. Further, the product patent has been already filed under fast track approval and the company is the first one in the Indian Market receiving the license and authorization to manufacture and market "FAVIPIRAVIR ORAL SUSPENSION 100mg/ml". Valuation Update With 7 Day Price Move • Apr 24
Investor sentiment improved over the past week After last week's 16% share price gain to ₹406, the stock trades at a trailing P/E ratio of 9.1x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 44% over the past three years. Is New 90 Day High Low • Feb 22
New 90-day low: ₹341 The company is down 4.0% from its price of ₹356 on 24 November 2020. The Indian market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 6.0% over the same period. Reported Earnings • Feb 12
Third quarter 2021 earnings released: EPS ₹9.46 (vs ₹14.11 in 3Q 2020) The company reported a poor third quarter result with weaker earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: ₹521.4m (down 30% from 3Q 2020). Net income: ₹54.1m (down 33% from 3Q 2020). Profit margin: 10% (in line with 3Q 2020). Is New 90 Day High Low • Nov 19
New 90-day low: ₹345 The company is down 24% from its price of ₹457 on 21 August 2020. The Indian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. Is New 90 Day High Low • Oct 29
New 90-day low: ₹365 The company is down 1.0% from its price of ₹370 on 31 July 2020. The Indian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period. Announcement • Sep 26
Bharat Parenterals Limited Announces Resignation of Monica Ahir, Company Secretary Bharat Parenterals Limited announced that Ms. Monica Ahir, Company Secretary & Compliance Officer of the Company has resigned from her post with effect from September 24, 2020. Announcement • Aug 14
Bharat Parenterals Limited to Report Q1, 2021 Results on Aug 20, 2020 Bharat Parenterals Limited announced that they will report Q1, 2021 results on Aug 20, 2020 Announcement • Jun 18
Bharat Parenterals Limited to Report Q4, 2020 Results on Jun 20, 2020 Bharat Parenterals Limited announced that they will report Q4, 2020 results on Jun 20, 2020 
